Each receptor pulls a different lever: GLP-1 curbs appetite and slows gastric emptying, GIP sharpens insulin secretion and may support lipid metabolism, and glucagon-receptor activation raises energy expenditure and drives fat oxidation [5] [8]
Bardzo dobra przyswajalno
GLP-1 Drugs on the Rise The Food and Drug Administration (FDA) has approved a new class of GLP-1 drugs, such as Wegovy, for treating obesity specifically, regardless of a patients history with or without type 2 diabetes
"Superior potency of infused IGF-I analogues which bind poorly to IGF-binding proteins is maintained when administered by injection." Journal of endocrinology 150.1 (1996): 77-84
Glucolipotoxicity: fuel excess and -cell dysfunction
Similarly, the instructions for taking the injection as it relates to consuming it with or without food, is similar